Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Nintedanib group:Nintedanib
Control group:Placebo
Sponsors
Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 70 years old; 2) Infection with new coronavirus pneumonia was confirmed by throat swab nucleic acid test. Patients with severe and critical illness were clinically judged. The symptoms of acute infection have been alleviated after treatment (at least 14 days after onset, no fever for more than 3 days), and the disease is recovering Within three months; 3) CT examination of patients with multiple fibrotic shadows in both lungs; 4) Blood routine, liver, and kidney functions are within the controllable range: such as the normal upper limit of plasma total bilirubin and creatinine =4.0x10^9/L, platelets >=100x10^9/L; 5) Signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Previous history of chronic bronchitis, emphysema, interstitial lung disease or pulmonary heart disease; 2) Combining with other serious diseases: such as those who have suffered myocardial infarction and uncontrollable diabetes within 6 months, and are considered unsuitable to participate in the trial; 3) People with active peptic ulcer; 4) Patients during pregnancy and lactation; 5) Patients with mental illness or others who cannot cooperate effectively; 6) Researcher judged unsuitable to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FVC; | — |
Secondary
| Measure | Time frame |
|---|---|
| DLco%;6MWT;HRCT score;Change in cough; | — |
Countries
China
Contacts
Public ContactXianglin Yuan
Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University
Outcome results
None listed